486 related articles for article (PubMed ID: 29524617)
21. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.
Bograd AJ; Suzuki K; Vertes E; Colovos C; Morales EA; Sadelain M; Adusumilli PS
Cancer Immunol Immunother; 2011 Nov; 60(11):1509-27. PubMed ID: 21913025
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.
Zauderer MG; Bott M; McMillan R; Sima CS; Rusch V; Krug LM; Ladanyi M
J Thorac Oncol; 2013 Nov; 8(11):1430-3. PubMed ID: 24128712
[TBL] [Abstract][Full Text] [Related]
23. Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS.
de Goeje PL; Klaver Y; Kaijen-Lambers MEH; Langerak AW; Vroman H; Kunert A; Lamers CHJ; Aerts JGJV; Debets R; Hendriks RW
Front Immunol; 2018; 9():2034. PubMed ID: 30245692
[No Abstract] [Full Text] [Related]
24. Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma.
Qualiotto AN; Baldavira CM; Balancin M; Ab'Saber A; Takagaki T; Capelozzi VL
Front Immunol; 2023; 14():1268927. PubMed ID: 37901248
[TBL] [Abstract][Full Text] [Related]
25. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
[TBL] [Abstract][Full Text] [Related]
26. Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators.
Hamaidia M; Staumont B; Duysinx B; Louis R; Willems L
Curr Top Med Chem; 2016; 16(7):777-87. PubMed ID: 26303419
[TBL] [Abstract][Full Text] [Related]
27. Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.
Tolani B; Acevedo LA; Hoang NT; He B
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342862
[TBL] [Abstract][Full Text] [Related]
28. The established and future biomarkers of malignant pleural mesothelioma.
Panou V; Vyberg M; Weinreich UM; Meristoudis C; Falkmer UG; Røe OD
Cancer Treat Rev; 2015 Jun; 41(6):486-95. PubMed ID: 25979846
[TBL] [Abstract][Full Text] [Related]
29. Current issues in malignant pleural mesothelioma evaluation and management.
Ai J; Stevenson JP
Oncologist; 2014 Sep; 19(9):975-84. PubMed ID: 25061089
[TBL] [Abstract][Full Text] [Related]
30. [Immunotherapy and malignant mesothelioma: clinical perspectives].
Grégoire M; Ebstein F
Bull Cancer; 2007 Jan; 94(1):23-31. PubMed ID: 17237002
[TBL] [Abstract][Full Text] [Related]
31. Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
Tamanna MT; Egbune C
Cancer Treat Res; 2023; 185():79-89. PubMed ID: 37306905
[TBL] [Abstract][Full Text] [Related]
32. Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial.
Katz SI; Roshkovan L; Berger I; Friedberg JS; Alley EW; Simone CB; Haas AR; Cengel KA; Sterman DH; Albelda SM
Lung Cancer; 2021 Apr; 154():5-12. PubMed ID: 33561782
[TBL] [Abstract][Full Text] [Related]
33. [Advances in Immunotherapy for Malignant Pleural Mesothelioma].
Chi Y; Liu Y; Zhao J
Zhongguo Fei Ai Za Zhi; 2022 Apr; 25(4):259-265. PubMed ID: 35477190
[TBL] [Abstract][Full Text] [Related]
34. [Systemic Treatment of Malignant Pleural Mesothelioma].
Nakano T
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2041-2047. PubMed ID: 29361614
[TBL] [Abstract][Full Text] [Related]
35. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
Srinivasan G; Sidhu GS; Williamson EA; Jaiswal AS; Najmunnisa N; Wilcoxen K; Jones D; George TJ; Hromas R
Cancer Chemother Pharmacol; 2017 Oct; 80(4):861-867. PubMed ID: 28756516
[TBL] [Abstract][Full Text] [Related]
36. Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.
Bononi A; Napolitano A; Pass HI; Yang H; Carbone M
Expert Rev Respir Med; 2015 Oct; 9(5):633-54. PubMed ID: 26308799
[TBL] [Abstract][Full Text] [Related]
37. Damage-associated molecular patterns and sensing receptors based molecular subtypes in malignant pleural mesothelioma and implications for immunotherapy.
Liu Z; Wan R; Bai H; Wang J
Front Immunol; 2023; 14():1104560. PubMed ID: 37033966
[TBL] [Abstract][Full Text] [Related]
38. Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach.
Lisini D; Lettieri S; Nava S; Accordino G; Frigerio S; Bortolotto C; Lancia A; Filippi AR; Agustoni F; Pandolfi L; Piloni D; Comoli P; Corsico AG; Stella GM
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445720
[TBL] [Abstract][Full Text] [Related]
39. BAP1 Deficiency Inflames the Tumor Immune Microenvironment and Is a Candidate Biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma.
Xu D; Gao Y; Yang H; Spils M; Marti TM; Losmanová T; Su M; Wang W; Zhou Q; Dorn P; Shu Y; Peng RW
JTO Clin Res Rep; 2024 May; 5(5):100672. PubMed ID: 38715965
[TBL] [Abstract][Full Text] [Related]
40. Progress in the Understanding of the Immune Microenvironment and Immunotherapy in Malignant Pleural Mesothelioma.
Cheng L; Li N; Xu XL; Mao WM
Curr Drug Targets; 2020; 21(15):1606-1612. PubMed ID: 32682370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]